CN-122005620-A - Application of bifidobacterium animalis in relieving respiratory allergy symptoms

Abstract

The invention discloses application of bifidobacterium animalis in relieving respiratory allergy symptoms, and belongs to the technical field of microorganisms. The technical problem to be solved is to provide the application of the bifidobacterium animalis in relieving the respiratory tract allergy symptoms, and the technical scheme is characterized in that the application of the bifidobacterium animalis subspecies BL-5M in relieving the respiratory tract allergy symptoms is realized, and the preservation number of the bifidobacterium animalis is CGMCC No.33449. The compound can act on the core mechanism of respiratory tract allergy, reduce sneeze/cough frequency caused by respiratory tract irritation and reflection, relieve lung tissue enlargement mediated by allergic inflammation, reduce the ratio of eosinophils in bronchoalveoli, reduce the concentration of pro-inflammatory factors IL-4 and IL-5 in bronchoalveoli, reduce inflammatory cell infiltration around the airway wall of the lung, reduce IgE content in the circulatory system or local tissues of the organism, improve intestinal flora diversity, accurately enrich anti-inflammatory functional flora and pertinently improve allergic asthma.

Inventors

• YANG MEI
• CUI LEI
• Jiang Rixiao
• CAI FENG
• LIU CHENG
• JIANG YUE
• MA DONGXUE
• ZHANG SHAOGANG

Assignees

• 中科微智（北京）生物科技有限公司

Dates

Publication Date

20260512

Application Date

20260313

Claims (10)

1. 1. Use of bifidobacterium animalis subspecies BL-5M or a fungicide comprising bifidobacterium animalis subspecies BL-5M or a preparation of bifidobacterium animalis subspecies BL-5M for the preparation of a composition with the effect of alleviating symptoms of respiratory allergies, characterized in that said bifidobacterium animalis subspecies BL-5M has a preservation number of CGMCC No.33449.
2. 2. The use according to claim 1, wherein the preparation of bifidobacterium animalis subspecies lactis BL-5M comprises fermentation broth, fermentation broth sediment, fermentation broth supernatant, viable bacteria, inactivated bacteria, lyophilized powder, lysate, secondary metabolites, exosomes.
3. 3. The use according to claim 1, wherein the composition has any one or more of the following functions: (1) Reducing the frequency of sneezing/coughing reflected by respiratory tract irritation; (2) Alleviating lung tissue enlargement mediated by allergic inflammation; (3) Reducing the eosinophil fraction in the bronchoalveolar lavage fluid; (4) Reducing the concentration of IL-4 in bronchoalveolar lavage fluid; (5) Reducing the concentration of IL-5 in bronchoalveolar lavage fluid; (6) Reducing inflammatory cell infiltration around the airway wall of the lung; (7) Reducing IgE content in circulatory system or local eye tissue of organism; (8) Improving intestinal flora diversity, enriching anti-inflammatory bacteria and remodelling flora steady state.
4. 4. Use according to claim 3, wherein the composition has any one or more of the following functions: (1) Reducing the frequency of reflex respiratory tract defensive response induced by respiratory tract stimulation; (2) Relieving inflammatory swelling state of lung tissue caused by allergic inflammation; (3) Reducing the relative content of eosinophils in the airway cavity liquid; (4) Reducing the level of inflammatory factors in airway cavity fluid; (5) Reducing inflammatory cell infiltration of lung tissue; (6) Reducing the content of sensitization antibody in the whole body of the organism; (7) Improving intestinal flora diversity, enriching anti-inflammatory bacteria and remodelling flora steady state.
5. 5. Use according to claim 1, characterized in that the bacterial content of the bifidobacterium animalis subspecies lactis BL-5M in the composition is not less than 1 x 10 8 CFU.
6. 6. The use according to claim 1, wherein the composition further comprises an adjuvant selected from any one or more of diluents, excipients, fillers, disintegrants, co-solvents, solubilisers, osmotic pressure regulators, surfactants, pH regulators, antioxidants.
7. 7. The use according to claim 1, wherein the composition is in the form of any one or more of a powder, a tablet, an emulsion, a pill, an ointment, a powder, a lyophilized powder for injection, a gel, a drop, a tincture, a capsule, a granule or an aerosol.
8. 8. The use according to any one of claims 1 to 7, wherein the respiratory allergy comprises allergic asthma, allergic rhinitis, allergic pharyngitis, allergic laryngitis, allergic bronchitis, allergic conjunctivitis.
9. 9. The use according to any one of claims 1 to 7, wherein the respiratory allergy is allergic asthma.
10. 10. The composition containing the bifidobacterium animalis subspecies BL-5M or the microbial inoculum containing the bifidobacterium animalis subspecies BL-5M or the preparation of the bifidobacterium animalis subspecies BL-5M is characterized in that the preservation number of the bifidobacterium animalis subspecies BL-5M is CGMCC No.33449, and the composition has the function of relieving respiratory allergy symptoms.

Description

Application of bifidobacterium animalis in relieving respiratory allergy symptoms Technical Field The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium animalis in relieving respiratory allergy symptoms. Background Respiratory allergies are a series of allergic diseases caused by allergen-induced immune dysfunction of the body, of which allergic asthma is a typical lower respiratory allergic disease. Allergic asthma takes chronic inflammation of the airway, airway hyperreactivity and reversible airflow limitation as core pathological characteristics, clinically presents symptoms such as wheeze, chest distress, cough, shortness of breath and the like, can cause dyspnea when severe, not only obviously reduces the life quality of patients, but also can endanger life due to acute attack. In addition to allergic asthma, respiratory allergy is often accompanied by symptoms such as allergic rhinitis, allergic pharyngitis, airway irritation reflex (sneeze, cough), and the like, and a plurality of parts such as lung, airway, immune organs, and the like can be involved in the disease progress process, so that a multidimensional abnormal chain of subjective symptoms, local physical signs, pathological indexes, immune functions is formed. Clinical researches show that the pathogenesis of allergic asthma is complex, the core is closely related to organism immune imbalance, after allergen invasion, the organism immune system is abnormally activated, so that the level of immunoglobulin (IgE) is obviously increased, igE is combined with mast cells and basophils to trigger the release of allergic media, meanwhile, th1/Th2 cell subgroup is unbalanced, inflammatory cytokines such as IL-4, IL-5 and the like are secreted by the overactivation of Th2 cells, inflammatory cells such as eosinophils and the like are induced to infiltrate into the lung airway, and further, the series of pathological manifestations such as lung swelling, airway inflammation, irritation and the like are caused, so that malignant circulation is formed. The current treatment means for respiratory tract allergy and allergic asthma mainly comprise symptomatic intervention, mainly glucocorticoid, bronchodilator, antihistamine, anti-IgE antibody medicine and the like. The antihistamine and the anti-IgE antibody medicine can inhibit allergic medium or IgE activity in a targeted manner, but the action target point is single, only partial symptoms can be improved, and the comprehensive regulation and control of multi-dimensional indexes are difficult to realize. The existing treatment scheme has the common limitations that most of medicaments are focused on local symptom relief, lack of accurate regulation on systemic immune imbalance, incapability of blocking the starting link of anaphylactic reaction, easy repeated attack of diseases and difficult realization of long-term control, and meanwhile, the existing treatment means have limited improvement effects on core pathological indexes such as lung swelling, inflammatory cell infiltration, inflammatory cytokines, eosinophilic abnormal rise and the like, and cannot meet the clinical requirements on efficient, comprehensive and low-side effect respiratory tract anaphylactic treatment scheme. In recent years, the association of intestinal microecology with systemic immune function has been widely demonstrated, and the theory of "intestinal-pulmonary axis" has clarified that intestinal flora balance can influence the occurrence and progression of respiratory diseases by regulating systemic immune response. The probiotics are used as a core carrier for regulating intestinal microecological balance, and can interfere with the immune imbalance state from the whole body level through the ways of colonizing intestinal tracts, regulating immune cell differentiation, regulating inflammatory factor secretion and the like, thereby providing a brand new direction for treating respiratory tract allergy. However, existing probiotic strains are mostly directed against intestinal health or broad-spectrum immunomodulation, lacking specific strains specifically directed against respiratory allergies. The related patent documents: Publication No. CN117487700A, publication No. 2024, month 02, discloses the use of Bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.lactis) CCFM1274 and/or fermentation broths of Bifidobacterium animalis subspecies CCFM1274, which has been deposited in the microorganism strain deposit center in Guangdong province at month 15 of 2022, for the preparation of a product for alleviating asthma symptoms, said Bifidobacterium animalis subspecies CCFM1274 being deposited under accession number GDMCC No:62798. The invention provides a method for relieving pathological characteristics of asthma mice, and further relieving allergic symptoms of the mice after the animal bifidobacterium lactis subspecies CCFM1274 acts on the asthm